27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) maintains an average price target of $203 — a 68.9-percent upside from the present price around $120.
Two firms offer targets of $300 or higher, and six foresee rates of at least $200.
Roundup
- Barclays: $205
- Citigroup: $275
- Cowen & Co.: $225
- FBR Capital: $200
- Oppenheimer: $200
- RBC Capital: $300
- Robert W. Baird: $332
- Wedbush: $224
Justification For Optimism
The inordinately large average target may signal analysts’ faith in Intercept’s obeticholic acid (OCA) treatment for nonalcoholic steatohepatitis (NASH). OCA is currently undergoing Phase 3 trials against the liver disease, and on Friday, Intercept announced that it altered its study protocol to accelerate results and improve chances of success. The U.S. Food and Drug Administration has already approved OCA to treat primary biliary cholangitis.
The optimism of analysts seemed to resonate with investors, who prompted shares to spike more than 7 percent Friday.
Nevertheless, three firms forecasting price raises maintain Sell or Hold ratings on the stock, while three additional firms predict significant downside.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!